Articles of Interest

CEPI - the Coalition for Epidemic Preparedness Innovations

We want to stop future epidemics by developing new vaccines for a safer world.

Vaccines are one of the world’s most important health achievements. Yet their life-saving potential hasn’t yet been realised for many known and unknown epidemic threats, particularly in low-income countries, where the risks and needs are often greatest...


A Global Plan to Defend Against the Future's Deadliest Diseases

$460 million will go toward developing vaccines that prevent outbreaks like Ebola from taking the world by surprise.

The closing days of 2016 brought great news: The world now has an Ebola vaccine that’s 100 percent effective at preventing infections from the strain behind the recent west African outbreak...


U.S. Travelers Skip Measles Vaccines, Study Finds

More than half of U.S. adults who should get vaccinated against measles before traveling abroad don’t do it, a new study suggests. The U.S. Centers for Disease Control and Prevention recommends two doses of the measles, mumps and rubella (MMR) vaccine for adults traveling outside the U.S. who were born before 1957 and lack either a documented measles infection, records of adequate vaccination or a positive blood test for immunity to measles. ...



Six Things YOU Need to Know about Vaccines

1. We all need vaccines throughout our lives to help protect against serious diseases. Every year, tens of thousands of Americans get sick from diseases that could be prevented by vaccines - some people are hospitalized, some even die. Immunization is our best protection against these diseases. Vaccines are recommended for children, teens, and adults based on different factors like age, health conditions, lifestyle, jobs, and travel...


Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
Featured Team Member

John H. Brown
President

John graduated with High Honors from Princeton in 1968 and received a Harvard MBA in 1970. He was Co-Head of Hamblet and Hayes from 1971 to 1980, when H&H was sold to CIBA-Geigy. During the next seventeen years John was with CIBA-Geigy (now renamed to Novartis), rising to become a Senior Vice President. During that period, he held many different positions including head of various points of Finance, Strategy, Business Development, Licensing, Policy, State and Federal Government Affairs, Pharmacoeconomics Research, QC/QA, Safety, Health, and Environment, and Regulatory Compliance. He also oversaw the over the counter business, CIBA-Corning Diagnostics, Biocine (a joint venture with Chiron in the Vaccine business), and the US Generics business.

After retiring from CIBA-Geigy, John was CEO of Covance Biotechnology Services, Inc., Research Triangle Park, NC, a contract manufacturer of Biopharma active ingredients (later sold to AKZO NOBEL), CEO of Integrated Biosystems, Inc., Napa, CA, a manufacturer of production equipment for Bio Pharmaceutical customers (e.g., Genentech, Amgen); (later sold to Stedim, SA, France); and President of Bausch & Lomb, London, where he oversaw Europe, Middle East & Africa. John had charge of the entire portfolio of eye care products (Surgical, Pharma, and Vision Care), representing around $2.5B in sales.

read more